Researchers at the Shandong Provincial Hospital in China have discovered that specific immune cells expressing the TREM2 protein help abnormal tissue survive and grow in the 200 million women worldwide affected by endometriosis.
Targeting Protein Shrinks Lesions
- The Immune Misdirection: Instead of clearing out misplaced uterine-like tissue, certain immune cells called macrophages actually protect the lesions and suppress other immune defenses.
- Protein Targeting: Laboratory tests show that blocking the TREM2 protein shrinks endometriosis lesions in mice and restores normal immune cell function.
- Hormone-Free Future: This discovery opens a potential pathway for non-hormonal treatments, though safety and efficacy in humans still need to be tested.
Immune System Mechanisms in Endometriosis
Endometriosis involves the growth of tissue resembling the uterine lining outside the uterus, frequently settling on the ovaries or within the abdominal cavity. This misplaced tissue triggers severe menstrual pain, chronic abdominal discomfort, and fertility challenges. While the exact origins of the condition remain unclear, medical science recognizes that the immune system plays a central role.
Ordinarily, the body relies on immune defenses to eliminate aberrant or damaged cells. Scientists studying tissue and peritoneal fluid samples from women with and without the condition identified a distinct population of macrophages carrying the TREM2 protein on their surface.
These TREM2-expressing macrophages actively hinder other critical defenders, including T-cells and natural killer cells, which normally target and destroy unwanted cells.
| Experimental Group | TREM2 Status | Lesion Size | Immune Cell Function |
|---|---|---|---|
| Control Mice | Normal (Active) | Baseline (Larger) | Suppressed T-cell activity |
| Knockout Mice | Genetically Disabled | Significantly Smaller | Improved T-cell and NK cell function |
| Antibody-Treated Mice | Blocked via Antibodies | Reduced | Restored cellular response |
Targeting TREM2 in Preclinical Models
To determine the functional impact of this protein, researchers utilized mouse models of endometriosis. Animals with a genetically disabled TREM2 gene developed significantly smaller lesions than the control group. Their T-cells and natural killer cells demonstrated improved operational capacity.
When the investigators subsequently depleted these specific macrophages, a portion of the therapeutic benefit vanished. This outcome indicates that the macrophages themselves are directly involved in modulating the progression of endometriosis lesions. Subsequent administration of antibodies designed to block TREM2 similarly yielded smaller lesions in the animal models.
Current medical management relies heavily on surgical intervention or hormone therapy.
Avoid Altering Treatment Plans
Because the TREM2-blocking approach remains in a preclinical phase of research, no clinical protocols exist for human use. Individuals undergoing current hormone therapies or surgical recovery must not alter their treatment plans based on experimental animal data, as TREM2 plays multiple complex roles throughout the human body that require rigorous safety validation.
The findings, detailed in Advanced Science, establish a framework for targeting the immune system rather than hormonal pathways. Investigators emphasize that human clinical trials are essential to confirm safety profiles and therapeutic efficacy before any non-hormonal treatments reach clinical practice.
References
- Advanced Science. Macrophage TREM2 signaling in endometriosis pathogenesis and immune evasion. Shandong Provincial Hospital research publication.
